Skip to main content
Senzime logo

Senzime — Investor Relations & Filings

Ticker · SEZI ISIN · SE0002478776 LEI · 549300JQF174JP0MM382 ST Manufacturing
Open in API
Filings indexed 216 across all filing types
Latest filing 2023-08-24 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SEZI

About Senzime

https://senzime.com/en

Senzime is a medical device company that develops and markets precision-based patient monitoring solutions designed to enhance patient safety. The company's primary focus is on systems for neuromuscular and respiratory monitoring during and after surgery. Its flagship product, the TetraGraph, is an algorithm-powered monitor that provides quantitative train-of-four (TOF) monitoring based on electromyography (EMG) technology. This enables clinicians to precisely manage neuromuscular blockade, reduce postoperative complications, and improve patient outcomes. Senzime's technology supports the adoption of new clinical guidelines, aiming to establish a higher standard of care in anesthesia and recovery.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT JANUARI – JUNI 2023' (Interim Report January – June 2023) and contains comprehensive financial statements, key performance indicators (KPIs), management commentary, and operational highlights for the specified period. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2023
2023-08-24 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report' and covers the period January–June 2023. It contains comprehensive financial statements, including net sales, EBITDA, profit/loss, earnings per share, and detailed management commentary on business performance, market trends, and operational KPIs. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-24 English
New number of shares and votes in Senzime AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release dated July 31, 2023, announcing a change in the total number of outstanding shares and votes due to a directed share issue authorized previously. It explicitly states the new total share count (87,622,614) and the resulting share capital. This directly relates to changes in the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA). It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it is a specific announcement about share count changes resulting from a capital action, SHA is the most precise fit over the general 'RNS' fallback.
2023-07-31 English
Förändrat antal aktier och röster i Senzime AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated July 31, 2023, titled "Förändrat antal aktier och röster i Senzime AB (publ)" (Change in the number of shares and votes in Senzime AB (publ)). It explicitly states that the total number of shares and the share capital have changed due to a directed new share issue decided on July 5, 2023. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a short announcement, the core content is the capital change itself, not just an announcement of a report, making SHA a better fit than RPA or RNS.
2023-07-31 Swedish
Utfall i riktad nyemission av aktier till säljare av Respiratory Motion
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated July 14, 2023, titled "Utfall i riktad nyemission av aktier till säljare av Respiratory Motion" (Outcome in directed new share issue to sellers of Respiratory Motion). It explicitly discusses the completion of a directed new share issue (nyemission av aktier) where 5,055,954 shares were subscribed and allotted. This action directly relates to changes in the company's capital structure through the issuance of new shares as part of an acquisition/transaction consideration. This aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it involves a transaction (TAR), the core announcement is the resulting share issuance, making SHA the most precise fit over CAP (which is broader financing) or TAR (which focuses on the M&A proposal itself). Given the document's nature as a formal announcement of a completed capital event, SHA is appropriate.
2023-07-14 Swedish
Outcome of directed share issue to sellers of Respiratory Motion
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated July 14, 2023, announcing the 'Outcome of directed share issue to sellers of Respiratory Motion'. It explicitly states that the Board of Directors resolved on a directed issue of shares and that 5,055,954 shares were subscribed and allocated. This action directly relates to changes in the company's capital structure through the issuance of new shares as part of an acquisition/transaction settlement. This aligns best with the 'Share Issue/Capital Change' category (SHA), as it details the finalization of a share issuance event. It is not a general financing update (CAP) but a specific execution of a share issuance.
2023-07-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.